e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Stem cells and growth factors in lung injury
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Transplant of alveolar type II cells restore pulmonary surfactant in lung fibrosis
G. Gay-Jordi, R. Gillamat, L. I. Sanchez, V. Sirenko, D. Closa, A. Xaubet, O. Bulbena, A. Serrano-Mollar (Barcelona, Spain)
Source:
Annual Congress 2010 - Stem cells and growth factors in lung injury
Session:
Stem cells and growth factors in lung injury
Session type:
Oral Presentation
Number:
209
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Gay-Jordi, R. Gillamat, L. I. Sanchez, V. Sirenko, D. Closa, A. Xaubet, O. Bulbena, A. Serrano-Mollar (Barcelona, Spain). Transplant of alveolar type II cells restore pulmonary surfactant in lung fibrosis. Eur Respir J 2010; 36: Suppl. 54, 209
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Risk factors associated with the development of interstitial lung abnormalities
Asbestosis
Related content which might interest you:
Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Transplantation of alveolar type II cells in pulmonary fibrosis: experimental studies, MSC in IPF trials
Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside
Year: 2014
Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Aging causes alveolar epithelial type II cell dysfunction in acute lung injury
Source: ERS Lung Science Conference 2020
Year: 2020
Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs
Source: Eur Respir J 2007; 29: 1105-1114
Year: 2007
Cytokine and chemokine release in response to
Pseudomonas aeruginosa
(PA), by bronchial epithelium of the native airway and transplanted lung of paediatric cystic fibrosis (CF) lung transplant recipients
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new basic and clinical physiology research
Year: 2012
Decreased VEGF concentration in lung tissue and vascular injury during ARDS
Source: Eur Respir J 2005; 25: 139-146
Year: 2005
Defective surfactant biosynthesis and ultrastructural abnormalities of alveolar type 2 cells in pulmonary fibrosis of conditional Nedd4-2mice
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Increased alveolar soluble annexin V promotes lung inflammation and fibrosis
Source: Eur Respir J 2015; 46: 1417-1429
Year: 2015
Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Infection and inflammation does not effect ventilation distribution in infants with cystic fibrosis (CF)
Source: Annual Congress 2011 - Cystic fibrosis: detection and monitoring of early lung disease
Year: 2011
Collagen I, III and IV content in airways and lung parenchyma of COPD patients
Source: Annual Congress 2010 - Proteases and the matrix
Year: 2010
New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015
Lung cysts in pulmonary alveolar proteinosis.
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
Increased expression of SARS-CoV-2 (Covid-19) adhesion sites on type II pneumocytes, small airway epithelium, and alveolar macrophages in smokers and patients with COPD
Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases
Year: 2021
Increased urotensin II in BALF and lung tissue in rat model of COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 216s
Year: 2006
Lung function and symptom improvement in patients with pulmonary alveolar proteinosis after whole lung lavage or N-acetylcysteine treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 83s
Year: 2005
Effects of DNase on pulmonary function and exercise capacity in cystic fibrosis (CF)
Source: Eur Respir J 2001; 18: Suppl. 33, 127s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept